Anesthesia Devices Market

Publisher Grand View Research

Published Jan 19, 2026

Length 150 Pages

SKU # GV20873210

Description

Anesthesia Devices Market Summary

The global anesthesia devices market size was estimated at USD 24.6 billion in 2025 and is projected to reach USD 30.3 billion by 2033, growing at a CAGR of 2.26% from 2026 to 2033. The market growth is driven by the increasing number of surgical procedures worldwide, the prevalence of chronic diseases, and technological advancements in anesthesia workstations and monitors

Increasing frequency of new and upgraded product launches by leading manufacturers is accelerating technology adoption and replacement demand across hospitals and surgical centers, contributing to the growth of the anesthesia machines industry. Major players are continuously introducing next-generation anesthesia workstations with enhanced safety features, advanced ventilation modes, improved ergonomics, digital integration, and sustainability-focused designs, addressing evolving clinical requirements across adult, pediatric, and neonatal care. For instance:

In October 2025, GE HealthCare launched the Carestation 850 anesthesia delivery system at ANESTHESIOLOGY 2025, featuring ergonomic design, customizable apps, advanced vaporization, sustainability tools, and intuitive UI to enhance precision and efficiency for diverse patients from neonates to adults.

“In the dynamic operating environment, anesthesia professionals are focused on safety while managing increasingly complex cases and changing patient needs. As anesthesia care teams face new challenges, technology can help ease the burden and support safer and more effective care delivery.”

-John Beard, MD, anesthesiologist and Chief Medical Officer of Patient Care Solutions at GE HealthCare.

In September 2025, Medisys launched the Made-in-India COSMOS anesthesia workstation, featuring a 15-inch advanced interface, integrated patient monitoring, and neonatal technology such as LED Phototherapy, at Medicall Delhi. This launch prioritized patient safety, clinician usability, and eco-friendly efficiency.

Such continuous innovation expands the clinical applicability of anesthesia machines, supports compliance with stricter safety and efficiency standards, and encourages healthcare providers to upgrade legacy systems, thereby strongly driving overall market growth and long-term demand for advanced anesthesia workstations.

A significant emerging trend in the anesthesia devices market is the integration of artificial intelligence (AI) and smart software, which is transforming the delivery of anesthesia care. AI-enabled algorithms support intelligent ventilation management, optimize anesthetic gas delivery using real-time patient data, enable predictive alarms to anticipate adverse events, and reduce clinician cognitive burden through automation and decision support.

These capabilities also improve workflow efficiency, standardize care across adult, pediatric, and neonatal populations, and enhance interoperability with perioperative IT systems. For instance, in January 2026, GE HealthCare collaborated with NXP Semiconductors to develop edge AI solutions for acute care, including voice-activated anesthesia delivery systems to reduce clinician cognitive load and real-time neonatal monitoring for NICUs, showcased at CES 2026; the partnership leverages NXP’s secure edge processors and GE HealthCare’s medical technology expertise to deliver low-latency, privacy-focused AI in operating rooms and other high-acuity settings. Thus, the growing integration of AI is making anesthesia devices smarter, safer, and more efficient, thereby accelerating the adoption of advanced anesthesia systems across modern healthcare facilities.

Global Anesthesia Devices Market Report Segmentation

This report forecasts revenue growth and provides at the global, regional, and country levels an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global anesthesia devices market report based on product, end use, and region:

Product Outlook (Revenue, USD Million, 2021 - 2033)
Anesthesia Machines
Anesthesia Workstation
Anesthesia delivery machines
Portable
Standalone
Anesthesia Ventilators
Anesthesia Monitors
Anesthesia Disposables
Anesthesia Masks
Anesthesia Accessories
End Use Outlook (Revenue, USD Million, 2021 - 2033)
Hospitals
Ambulatory Centers
Others
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait

Please note The report will be delivered in 2-3 business days upon order notification.

Chapter 1. Methodology and Scope: 1.1. Market Segmentation and Scope; 1.1.1. Technology Segment; 1.1.2. Application Segment; 1.1.3. End Use Segment; 1.2. Regional Scope; 1.3. Estimates and Forecast Timeline; 1.4. Research Methodology; 1.5. Information Procurement; 1.5.1. Purchased Database; 1.5.2. GVR’s Internal Database; 1.5.3. Secondary Sources; 1.5.4. Primary Research; 1.6. Information or Data Analysis:; 1.6.1. Data Analysis Models; 1.7. Market Formulation & Validation; 1.8. Model Details; 1.8.1. Commodity Flow Analysis; 1.9. Objectives
Chapter 2. Executive Summary: 2.1. Market Outlook; 2.2. Segment Snapshot; 2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope: 3.1. Market Lineage Outlook; 3.1.1. Parent Market Outlook; 3.1.2. Related/Ancillary Market Outlook; 3.2. Market Dynamics; 3.2.1. Market Driver Analysis; 3.2.1.1. Increasing demand for organ transplantation & tissue engineering; 3.2.1.2. Technological advancements in scaffold free technology; 3.2.1.3. Rise in investments and R&D funding for cell-based research; 3.2.1.4. Increasing focus on developing alternative to animal testing; 3.2.2. Market Restraint Analysis; 3.2.2.1. High cost associated with implementation; 3.2.2.2. Lack of compatibility and consistency; 3.3. Industry Analysis Tools; 3.3.1. Porter’s Five Forces Analysis; 3.3.2. PESTEL Analysis
Chapter 4. Technology Business Analysis: 4.1. Technology Segment Dashboard; 4.2. Global 3D Cell Culture Market Technology Movement Analysis; 4.3. Global 3D Cell Culture Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Million); 4.4. Scaffold Based; 4.4.1. Scaffold based market estimates and forecasts, 2021 - 2033 (USD Million); 4.4.2. Hydrogels; 4.4.2.1. Hydrogels market estimates and forecasts, 2021 - 2033 (USD Million); 4.4.3. Polymeric Scaffolds; 4.4.3.1. Polymeric scaffolds market estimates and forecasts, 2021 - 2033 (USD Million); 4.4.4. Micropatterned Surface Microplates; 4.4.4.1. Micropatterned surface microplates market estimates and forecasts, 2021 - 2033 (USD Million); 4.4.5. Nanofiber Based Scaffolds; 4.4.5.1. Nanofiber based scaffolds market estimates and forecasts, 2021 - 2033 (USD Million); 4.5. Scaffold Free; 4.5.1. Scaffold free market estimates and forecasts, 2021 - 2033 (USD Million); 4.5.2. Hanging Drop Microplates; 4.5.2.1. Hanging drop microplates market estimates and forecasts, 2021 - 2033 (USD Million); 4.5.3. Spheroid Microplates with ULA coating; 4.5.3.1. Spheroid microplates with ULA coating market estimates and forecasts, 2021 - 2033 (USD Million); 4.5.4. Magnetic Levitation; 4.5.4.1. Magnetic levitation market estimates and forecasts, 2021 - 2033 (USD Million); 4.6. Bioreactors; 4.6.1. Bioreactors market estimates and forecasts, 2021 - 2033 (USD Million); 4.7. Microfluidics; 4.7.1. Microfluidics market estimates and forecasts, 2021 - 2033 (USD Million); 4.8. Bioprinting; 4.8.1. Bioprinting market estimates and forecasts, 2021 - 2033 (USD Million)
Chapter 5. Application Business Analysis: 5.1. Application Segment Dashboard; 5.2. Global 3D Cell Culture Market Application Movement Analysis; 5.3. Global 3D Cell Culture Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million); 5.4. Cancer Research; 5.4.1. Cancer research market estimates and forecasts, 2021 - 2033 (USD Million); 5.5. Stem Cell Research & Tissue Engineering; 5.5.1. Stem cell research & tissue engineering market estimates and forecasts, 2021 - 2033 (USD Million); 5.6. Drug Development & Toxicity Testing; 5.6.1. Drug development & toxicity testing market estimates and forecasts, 2021 - 2033 (USD Million); 5.7. Others; 5.7.1. Others market estimates and forecasts, 2021 - 2033 (USD Million)
Chapter 6. End Use Business Analysis: 6.1. End Use Segment Dashboard; 6.2. Global 3D Cell Culture Market End Use Movement Analysis; 6.3. Global 3D Cell Culture Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million); 6.4. Biotechnology & Pharmaceutical Companies; 6.4.1. Biotechnology & pharmaceutical companies market estimates and forecasts, 2021 - 2033 (USD Million); 6.5. Academic & Research Institutes; 6.5.1. Academic & research institutes market estimates and forecasts, 2021 - 2033 (USD Million); 6.6. Hospitals; 6.6.1. Hospital market estimates and forecasts, 2021 - 2033 (USD Million); 6.7. Others; 6.7.1. Others market estimates and forecasts, 2021 - 2033 (USD Million)
Chapter 7. Regional Business Analysis: 7.1. Regional Dashboard; 7.2. Market Size & Forecasts and Trend Analysis, 2021 to 2033; 7.3. North America; 7.3.1. North America 3D Cell Culture, 2021 - 2033 (USD Million); 7.3.2. U.S.; 7.3.2.1. Key Country Dynamics; 7.3.2.2. Competitive Scenario; 7.3.2.3. Regulatory Framework; 7.3.2.4. U.S. 3D Cell Culture, 2021 - 2033 (USD Million); 7.3.3. Canada; 7.3.3.1. Key Country Dynamics; 7.3.3.2. Competitive Scenario; 7.3.3.3. Regulatory Framework; 7.3.3.4. Canada 3D Cell Culture, 2021 - 2033 (USD Million); 7.3.4. Mexico; 7.3.4.1. Key Country Dynamics; 7.3.4.2. Competitive Scenario; 7.3.4.3. Regulatory Framework; 7.3.4.4. Mexico 3D Cell Culture, 2021 - 2033 (USD Million); 7.4. Europe; 7.4.1. Europe 3D Cell Culture, 2021 - 2033 (USD Million); 7.4.2. UK; 7.4.2.1. Key Country Dynamics; 7.4.2.2. Competitive Scenario; 7.4.2.3. Regulatory Framework; 7.4.2.4. UK 3D Cell Culture, 2021 - 2033 (USD Million); 7.4.3. Germany; 7.4.3.1. Key Country Dynamics; 7.4.3.2. Competitive Scenario; 7.4.3.3. Regulatory Framework; 7.4.3.4. Germany 3D Cell Culture, 2021 - 2033 (USD Million); 7.4.4. France; 7.4.4.1. Key Country Dynamics; 7.4.4.2. Competitive Scenario; 7.4.4.3. Regulatory Framework; 7.4.4.4. France 3D Cell Culture, 2021 - 2033 (USD Million); 7.4.5. Italy; 7.4.5.1. Key Country Dynamics; 7.4.5.2. Competitive Scenario; 7.4.5.3. Regulatory Framework; 7.4.5.4. Italy 3D Cell Culture, 2021 - 2033 (USD Million); 7.4.6. Spain; 7.4.6.1. Key Country Dynamics; 7.4.6.2. Competitive Scenario; 7.4.6.3. Regulatory Framework; 7.4.6.4. Spain 3D Cell Culture, 2021 - 2033 (USD Million); 7.4.7. Denmark; 7.4.7.1. Key Country Dynamics; 7.4.7.2. Competitive Scenario; 7.4.7.3. Regulatory Framework; 7.4.7.4. Denmark 3D Cell Culture, 2021 - 2033 (USD Million); 7.4.8. Sweden; 7.4.8.1. Key Country Dynamics; 7.4.8.2. Competitive Scenario; 7.4.8.3. Regulatory Framework; 7.4.8.4. Sweden 3D Cell Culture, 2021 - 2033 (USD Million); 7.4.9. Norway; 7.4.9.1. Key Country Dynamics; 7.4.9.2. Competitive Scenario; 7.4.9.3. Regulatory Framework; 7.4.9.4. Norway 3D Cell Culture, 2021 - 2033 (USD Million); 7.5. Asia Pacific; 7.5.1. Asia Pacific 3D Cell Culture, 2021 - 2033 (USD Million); 7.5.2. Japan; 7.5.2.1. Key Country Dynamics; 7.5.2.2. Competitive Scenario; 7.5.2.3. Regulatory Framework; 7.5.2.4. Japan 3D Cell Culture, 2021 - 2033 (USD Million); 7.5.3. China; 7.5.3.1. Key Country Dynamics; 7.5.3.2. Competitive Scenario; 7.5.3.3. Regulatory Framework; 7.5.3.4. China 3D Cell Culture, 2021 - 2033 (USD Million); 7.5.4. India; 7.5.4.1. Key Country Dynamics; 7.5.4.2. Competitive Scenario; 7.5.4.3. Regulatory Framework; 7.5.4.4. India 3D Cell Culture, 2021 - 2033 (USD Million); 7.5.5. Australia; 7.5.5.1. Key Country Dynamics; 7.5.5.2. Competitive Scenario; 7.5.5.3. Regulatory Framework; 7.5.5.4. Australia 3D Cell Culture, 2021 - 2033 (USD Million); 7.5.6. Thailand; 7.5.6.1. Key Country Dynamics; 7.5.6.2. Competitive Scenario; 7.5.6.3. Regulatory Framework; 7.5.6.4. Thailand 3D Cell Culture, 2021 - 2033 (USD Million); 7.5.7. South Korea; 7.5.7.1. Key Country Dynamics; 7.5.7.2. Competitive Scenario; 7.5.7.3. Regulatory Framework; 7.5.7.4. South Korea 3D Cell Culture, 2021 - 2033 (USD Million); 7.6. Latin America; 7.6.1. Latin America 3D Cell Culture, 2021 - 2033 (USD Million); 7.6.2. Brazil; 7.6.2.1. Key Country Dynamics; 7.6.2.2. Competitive Scenario; 7.6.2.3. Regulatory Framework; 7.6.2.4. Brazil 3D Cell Culture, 2021 - 2033 (USD Million); 7.6.3. Argentina; 7.6.3.1. Key Country Dynamics; 7.6.3.2. Competitive Scenario; 7.6.3.3. Regulatory Framework; 7.6.3.4. Argentina 3D Cell Culture, 2021 - 2033 (USD Million); 7.7. MEA; 7.7.1. MEA 3D Cell Culture, 2021 - 2033 (USD Million); 7.7.2. South Africa; 7.7.2.1. Key Country Dynamics; 7.7.2.2. Competitive Scenario; 7.7.2.3. Regulatory Framework; 7.7.2.4. South Africa 3D Cell Culture, 2021 - 2033 (USD Million); 7.7.3. Saudi Arabia; 7.7.3.1. Key Country Dynamics; 7.7.3.2. Competitive Scenario; 7.7.3.3. Regulatory Framework; 7.7.3.4. Saudi Arabia 3D Cell Culture, 2021 - 2033 (USD Million); 7.7.4. UAE; 7.7.4.1. Key Country Dynamics; 7.7.4.2. Competitive Scenario; 7.7.4.3. Regulatory Framework; 7.7.4.4. UAE 3D Cell Culture, 2021 - 2033 (USD Million); 7.7.5. Kuwait; 7.7.5.1. Key Country Dynamics; 7.7.5.2. Competitive Scenario; 7.7.5.3. Regulatory Framework; 7.7.5.4. Kuwait 3D Cell Culture, 2021 - 2033 (USD Million)
Chapter 8. Competitive Landscape: 8.1. Company Categorization; 8.2. Strategy Mapping; 8.3. Company Market Position Analysis, 2025; 8.4. Company Profiles/Listing; 8.4.1. Thermo Fisher Scientific, Inc; 8.4.1.1. Overview; 8.4.1.2. Financial Performance; 8.4.1.3. Product Benchmarking; 8.4.1.4. Strategic Initiatives; 8.4.2. Merck KGaA; 8.4.2.1. Overview; 8.4.2.2. Financial Performance; 8.4.2.3. Product Benchmarking; 8.4.2.4. Strategic Initiatives; 8.4.3. PromoCell GmbH; 8.4.3.1. Overview; 8.4.3.2. Financial Performance; 8.4.3.3. Product Benchmarking; 8.4.3.4. Strategic Initiatives; 8.4.4. Lonza; 8.4.4.1. Overview; 8.4.4.2. Financial Performance; 8.4.4.3. Product Benchmarking; 8.4.4.4. Strategic Initiatives; 8.4.5. Corning Incorporated; 8.4.5.1. Overview; 8.4.5.2. Financial Performance; 8.4.5.3. Product Benchmarking; 8.4.5.4. Strategic Initiatives; 8.4.6. Avantor, Inc.; 8.4.6.1. Overview; 8.4.6.2. Financial Performance; 8.4.6.3. Product Benchmarking; 8.4.6.4. Strategic Initiatives; 8.4.7. Tecan Trading AG; 8.4.7.1. Overview; 8.4.7.2. Financial Performance; 8.4.7.3. Product Benchmarking; 8.4.7.4. Strategic Initiatives; 8.4.8. REPROCELL Inc.; 8.4.8.1. Overview; 8.4.8.2. Financial Performance; 8.4.8.3. Product Benchmarking; 8.4.8.4. Strategic Initiatives; 8.4.9. CN Bio Innovations Ltd.; 8.4.9.1. Overview; 8.4.9.2. Financial Performance; 8.4.9.3. Product Benchmarking; 8.4.9.4. Strategic Initiatives; 8.4.10. Lena Biosciences; 8.4.10.1. Overview; 8.4.10.2. Financial Performance; 8.4.10.3. Product Benchmarking; 8.4.10.4. Strategic Initiatives

Pricing

Currency Rates

Single User Email from Publisher $5,950
Multi User License Fulfilled by Publisher $6,950
Global Site License Email from Publisher $8,950

How Do Licenses Work?

Request A Sample

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

Chat Now